Affimed NV (NASDAQ:AFMD) has earned an average recommendation of “Hold” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $4.81.
Several equities research analysts have recently weighed in on the company. ValuEngine raised Affimed from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 28th. BidaskClub raised Affimed from a “strong sell” rating to a “sell” rating in a research note on Friday, August 31st. Jefferies Financial Group raised Affimed from a “hold” rating to a “buy” rating and increased their price target for the company from $1.80 to $4.00 in a research note on Tuesday, August 28th. Zacks Investment Research raised Affimed from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research note on Tuesday, October 9th. Finally, SunTrust Banks decreased their price target on Affimed to $5.00 and set a “buy” rating for the company in a research note on Thursday, October 11th.
Hedge funds have recently modified their holdings of the company. Canada Pension Plan Investment Board acquired a new stake in shares of Affimed in the second quarter valued at about $165,000. Dimensional Fund Advisors LP boosted its position in shares of Affimed by 28.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 319,871 shares of the biopharmaceutical company’s stock valued at $592,000 after purchasing an additional 71,545 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Affimed during the 1st quarter valued at about $4,731,000. Stanley Laman Group Ltd. bought a new stake in shares of Affimed during the 2nd quarter valued at about $100,000. Finally, Barclays PLC boosted its position in shares of Affimed by 385.3% during the 1st quarter. Barclays PLC now owns 64,958 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 51,573 shares in the last quarter. 40.63% of the stock is owned by institutional investors.
Shares of AFMD stock opened at $3.21 on Friday. The stock has a market capitalization of $210.26 million, a PE ratio of -4.12 and a beta of 3.56. The company has a quick ratio of 5.33, a current ratio of 5.36 and a debt-to-equity ratio of 0.06. Affimed has a 1-year low of $1.15 and a 1-year high of $7.35.
Affimed (NASDAQ:AFMD) last issued its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. The company had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.61 million. Affimed had a negative return on equity of 74.04% and a negative net margin of 1,723.04%. As a group, research analysts predict that Affimed will post -0.61 earnings per share for the current year.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Article: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.